Business Description
NurExone Biologic Inc
NAICS : 325412
SIC : 3741
ISIN : CA67059R1091
Compare
Compare
Traded in other countries / regions
NRX.CanadaJ90.GermanyNRXBF.USA IPO Date
2023-08-22Description
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 137.69 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate | 13.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.47 | |||||
| 9-Day RSI | 40.13 | |||||
| 14-Day RSI | 42.92 | |||||
| 6-1 Month Momentum % | -27.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.16 | |||||
| Quick Ratio | 10.16 | |||||
| Cash Ratio | 8.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -1.79 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -289.11 | |||||
| ROA % | -174.81 | |||||
| ROIC % | -780.77 | |||||
| ROC (Joel Greenblatt) % | -1785.47 | |||||
| ROCE % | -269.31 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 7.92 | |||||
| Price-to-Tangible-Book | 7.92 | |||||
| EV-to-EBIT | -7.18 | |||||
| EV-to-EBITDA | -7.26 | |||||
| EV-to-FCF | -7.1 | |||||
| Price-to-Net-Current-Asset-Value | 9.5 | |||||
| Price-to-Net-Cash | 11.87 | |||||
| Earnings Yield (Greenblatt) % | -13.93 | |||||
| FCF Yield % | -11.44 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers